Vatalanib in Treating Patients With Recurrent or Progressive Meningioma

Phase 2

Completed

• Conditions: Brain and Central Nervous System Tumors; Sarcoma
• Interventions: Drug: vatalanib

• Registration Number: NCT00348790
• Lead Sponsor: Northwestern University

Brief Summary

RATIONALE: Vatalanib may stop the growth of tumor cells by blocking blood flow to the tumor and by blocking some of the enzymes needed for cell growth.

PURPOSE: This phase II trial is studying how well vatalanib works in treating patients with recurrent or progressive meningioma.

Detailed Description

OBJECTIVES:

Primary

* Determine the efficacy of vatalanib, in terms of radiographic improvement and clinical improvement, in patients with recurrent or progressive meningioma.

Secondary

* Determine the 6-month progression-free survival of these patients.

* Describe the response rate and overall survival of these patients.

* Determine the safety of vatalanib in these patients.

* Correlate the response rates with expression of vascular endothelial growth factor, epidermal growth factor receptor, platelet-derived growth factor, and HER2.

* Develop exploratory data concerning surrogate markers of angiogenic activity in vivo using magnetic resonance perfusion.

OUTLINE: Patients receive oral vatalanib twice daily on days 1-28. Courses repeat every 28 days for 1 year in the absence of disease progression or unacceptable toxicity.

After completion of study treatment, patients are followed for 1 year.

PROJECTED ACCRUAL: A total of 25 patients will be accrued for this study.

Study Timeline

• Study Start: 2006-05
• Study First Submitted: 2006-07-05
• Study First Submitted QC: 2006-07-05
• Study First Posted: 2006-07-06
• Primary Completion: 2010-11
• Study Completion: 2013-07
• Results First Submitted: 2014-10-21
• Results First Submitted QC: 2014-10-21
• Results First Posted: 2014-10-27
• Status Verified: 2018-10
• Last Update Submitted: 2018-10-24
• Last Update Posted: 2018-10-26

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 25

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Vatalanib	vatalanib	Patients will be treated with 500 mg of vatalanib, administered orally, twice a day for 28 days (1 cycle). Patients will start at a dose of 250 mg twice a day and increase by 250 mg per day every 7 days until 500 mg twice a day is reached. Patients who are responding may remain on study treatment for 12 months.

Primary Outcome Measures

Name	Time	Method
Number of Patients Who DID NOT Experience Disease Progression or Death by 6 Months After Starting Treatment.	From the date the first patient began treatment until the date the last patient has disease progression, becomes deceased, or completes 6 months of treatment	Patients were assessed with imaging techniques (MRI) during screening/baseline and then every 2 months after starting treatment. Survival status and disease status were recorded. The number of patients who did not experience an event (defined as either death for any reason or progression of their disease) by 6 months after starting treatment were counted.

Secondary Outcome Measures

Name	Time	Method
Determine Efficacy (Radiographic and Clinical Improvement)	At baseline, every 2 weeks for 2 months, then every 8 weeks while on treatment	Efficacy will be assessed by MRI scan and neurological exam upon study entry, every 2 weeks for 2 months, then every 8 weeks while on treatment
Best Overall Response Rate (ORR)	Every 2 months for up to 1 year after study treatment.	Overall Response Rate (ORR) will be as assessed by MRI scan every 2 months while on study treatment and follow-up for up to 1 year after discontinuation of study treatment. The RR is the best response recorded from the start of the treatment until disease progression (PD) where the following definitions apply.; Complete Response (CR): Complete disappearance of all measurable and evaluable disease. No new lesions.; Partial Response (PR): Greater than or equal to 50% decrease under baseline in the sum of products of perpendicular diameters of all measurable lesions. No progression of evaluable disease. No new lesions.; Stable/No Response: Does not qualify for CR, PR, or PD Progressive disease (PD):25% increase in the sum of products of all measurable lesions over smallest sum observed (over baseline if no decrease) worsening of evaluable disease, new lesions, clinical worsening OR failure to return for evaluation due to death/deteriorating condition
To Correlate the Response Rates With Expression of Certain Types of Genes	At the end of study treatment	Correlation of response rates with the expression of certain types of genes will be assessed by examining tissue samples taken from previous surgery and testing for certain genes
Safety of Vatalanib in Patients With Recurrent of Progressive Meningiomas	Every week while on study treatment until 30 days after last treatment.	Safety of vatalanib will be assessed using National Cancer Institute Common Terminology Criteria of Adverse Events (NCI CTCAE) 3.0 and graded using the following: Grade 1 = Mild Grade 2 = Moderate Grade 3 = Severe Grade 4 = Life threatening Grade 5 = Fatal
Number of Months Patients Survive After Being Treatment on the Study.	From the date the first patient began treatment until the date the last patient became deceased.
Overall Survival (OS)	Every 2 months for up to 1 year after study treatment.	Overall Survival will be measured from the first treatment on study until death of any cause.

Trial Locations

Locations (3)

Robert H. Lurie Comprehensive Cancer Center at Northwestern University; 🇺🇸 Chicago, Illinois, United States

Hematology-Oncology Associates of Illinois; 🇺🇸 Chicago, Illinois, United States

University Cancer Center at University of Washington Medical Center; 🇺🇸 Seattle, Washington, United States